Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics...

Mylan Announces Strategic Collaboration with Biocon to Enter the Global
Generic Biologics Market

PITTSBURGH, June 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today
announced that it has executed a definitive agreement with Biocon Limited, a
publicly traded company on the Indian stock exchanges, for an exclusive
collaboration on the development, manufacturing, supply and commercialization
of multiple, high value generic biologic compounds for the global marketplace.
Through this partnership, Mylan and Biocon bring together highly complementary
capabilities that will significantly advance their efforts to secure a leading
position in the emerging generic biologics industry.

Mylan's Chairman and CEO Robert J. Coury commented: "Biocon is a first-class,
highly respected organization, and I am extremely excited to be able to
announce what I consider to be one of the more comprehensive and high quality
biologics initiatives reported within the industry to date. After working with
our Senior Vice President and Head of Global Biologics Dr. Patrick Vink and
conducting extensive due diligence, I can tell you that Biocon is truly an
ideal partner for Mylan."

Coury continued: "This unique collaboration combines Biocon's scientific
expertise; excellent product development track record; appreciation of complex
regulatory requirements; and state-of-the-art, cost-efficient and scalable
biologics manufacturing with Mylan's one-of-a-kind global commercial footprint
and our regulatory expertise around the world. Biocon also has a unique
corporate culture that is very similar to Mylan's. All of these attributes
will provide a critical synergy and create a strong and effective long-term
partnership. Generic biologics, especially monoclonal antibodies, are expected
to become the next great bolus of growth in the generic pharmaceutical
industry, and through this alliance, Mylan and Biocon have covered all four
corners of what any organization would want or need to have secured to offer a
highly competitive and distinct generic biologics product portfolio with
tremendous growth potential for the coming decade."

Biocon Chairman and Managing Director Dr. Kiran Mazumdar-Shaw commented:
"Biocon is extremely pleased to have found a partner as strong as Mylan to
accelerate our work in generic biologics, especially with monoclonal
antibodies, and take it to the next level around the world, especially in
regulated markets. I am confident that our shared vision for the sector,
complementary skills, mutual respect and work ethic will make this
collaboration a remarkable success while bringing additional value to Biocon
and its shareholders. Monoclonal antibodies are emerging as the most dominant
class in biologics. Through this partnership we hope to deliver high quality,
affordable biogeneric antibodies and biologics, thereby addressing a critical
need to lower spiraling healthcare costs in both the developed and emerging
economies."

As part of this collaboration, Mylan and Biocon will share development,
capital and certain other costs to bring products to market. Mylan will have
exclusive commercialization rights in the U.S., Canada, Japan, Australia, New
Zealand and in the European Union and European Free Trade Association
countries through a profit sharing arrangement with Biocon. Mylan will have
co-exclusive commercialization rights with Biocon in all other markets around
the world. All other financial terms and product details remain confidential.

Mylan Inc., which provides products to customers in more than 140 countries
and territories, ranks among the leading diversified generics and specialty
pharmaceutical companies in the world. The company maintains one of the
industry's broadest -- and highest quality -- product portfolios, supported by
a robust product pipeline; owns a controlling interest in the world's third
largest active pharmaceutical ingredient manufacturer; and operates a
specialty business focused on respiratory and allergy therapies. For more
information, visit www.mylan.com.

Established in 1978, Biocon Limited is one of India's premier biotechnology
companies. Together with its group companies, Biocon forms a fully integrated
biotechnology enterprise, specializing in biopharmaceuticals, custom research
and clinical research, which deliver products and solutions to partners and
customers across the globe. Biocon launched the world's first recombinant
human insulin, INSUGEN(R) in November 2004 using Pichia expression and India's
first indigenously produced monoclonal antibody BIOMAb-EGFR(TM). Focusing on
unmet medical needs in cancer, diabetes and inflammatory diseases, Biocon
offers novel therapies on a platform of affordable innovation. Biocon's
strategic licensing partnerships provide market penetration and global access
to deliver breakthrough therapeutics to millions of patients the world over.
For more information, visit www.biocon.com.

This press release includes statements that constitute "forward-looking
statements," including with regard to the collaboration and commercialization
of the products and the company's future opportunities. These statements are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Because such statements inherently involve
risks and uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause or contribute to such differences include, but are not limited to:
the content and timing of decisions by regulatory authorities related to the
development and commercialization of the products; difficulties or delays in
manufacturing; demand for and market acceptance for the products; the impact
of competitive products and pricing; and the other risks detailed in the
company's periodic filings with the Securities and Exchange Commission. The
company undertakes no obligation to update these statements for revisions or
changes after the date of this release.

SOURCE Mylan Inc.

Michael Laffin (Media), +1-724-514-1968, or Dan Crookshank (Investors),
+1-724-514-1813, both of Mylan Inc.